Decrease in Serum Albumin Level Predicts Onset of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Relapsed/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel) | Zendy

Zaid Abdel Rahman | Zendy; Sangeetha Gandhi | Zendy; Megan Melody | Zendy; Muhamad Alhaj Moustafa | Zendy; Nicole Gan | Zendy; Paula A. Lengerke-Diaz | Zendy; Tuan Truong | Zendy; Mattia Novo | Zendy; Eva Brandes | Zendy; Gina Lange | Zendy; Breanna Estby | Zendy; Ernesto Ayala | Zendy; Hemant S. Murthy | Zendy; Stephen M. Ansell | Zendy; Jonas Paludo | Zendy; Patrick B. Johnston | Zendy; Allison Rosenthal | Zendy; N. Nora Bennani | Zendy; José C. Villasboas | Zendy; Han W. Tun | Zendy; James M. Foran | Zendy; Januario E. Castro | Zendy; Yi Lin | Zendy; Mohamed A. KharfanDabaja | Zendy

Open Access

Decrease in Serum Albumin Level Predicts Onset of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Relapsed/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Author(s) -

Zaid Abdel Rahman,

Sangeetha Gandhi,

Megan Melody,

Muhamad Alhaj Moustafa,

Nicole Gan,

Paula A. Lengerke-Diaz,

Tuan Truong,

Mattia Novo,

Eva Brandes,

Gina Lange,

Breanna Estby,

Ernesto Ayala,

Hemant S. Murthy,

Stephen M. Ansell,

Jonas Paludo,

Patrick B. Johnston,

Allison Rosenthal,

N. Nora Bennani,

José C. Villasboas,

Han W. Tun,

James M. Foran,

Januario E. Castro,

Yi Lin,

Mohamed A. KharfanDabaja

Publication year - 2020

Publication title -

biology of blood and marrow transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.301

H-Index - 120

eISSN - 1523-6536

pISSN - 1083-8791

DOI - 10.1016/j.bbmt.2019.12.425

Subject(s) - medicine , cytokine release syndrome , albumin , gastroenterology , refractory (planetary science) , oncology , immunology , cancer , immunotherapy , physics , chimeric antigen receptor , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research